EP. 1: DLBCL: Circumstances for Deviating Away From R-CHOP
EP. 2: DLBCL: Treatment Considerations for Challenging Populations
EP. 3: DLBCL: Treating Patients Following Relapse on Frontline Therapy
EP. 4: R/R DLBCL: Second-Line Treatment Options
EP. 5: Tafasitamab Combined With Lenalidomide in R/R DLBCL
EP. 6: R/R DLBCL: Treating With Tafasitamab-Lenalidomide
EP. 7: Novel Therapies for R/R DLBCL
EP. 8: CAR T-Cell Therapy for R/R DLBCL
EP. 9: CAR-T Treatment Options for R/R DLBCL
EP. 10: Treating R/R DLBCL With CAR-T: Current Barriers
EP. 11: Understanding the CAR-T Process: Collection Through Infusion
EP. 12: CAR T for R/R DLBCL: Safety/Tolerability
EP. 13: CAR T for R/R DLBCL: Improving Access and Utilization
EP. 14: R/R DLBCL: Transplants in the Era of CAR-T
EP. 15: Bridging Therapy in R/R DLBCL
EP. 16: Treating Primary Refractory DLBCL
EP. 17: R/R DLBCL: Novel Therapies in the Pipeline
EP. 18: R/R DLBCL: A Glance at Using Novel Therapies Moving Forward
EP. 19: Evolving Therapies in R/R DLBCL: Concluding Remarks
Axatilimab Elicits Responses With Manageable Safety in Recurrent/Refractory cGVHD
Dr Bal on Updated Findings With BMS-986393 in Relapsed/Refractory Multiple Myeloma
Dr Ghia on a Biomarker Analysis of the SEQUOIA Trial in CLL/SLL
Oral DEC-C Treatment Is Feasible and Comparable With IV/SC HMA Outcomes in MDS
